Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $20.50 and last traded at $19.12, with a volume of 4225029 shares. The stock had previously closed at $10.60.
Analyst Ratings Changes
Several analysts have weighed in on GHRS shares. Canaccord Genuity Group lowered their target price on GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, November 18th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of GH Research in a research report on Monday, January 27th.
Read Our Latest Report on GHRS
GH Research Price Performance
The firm has a market capitalization of $702.93 million, a PE ratio of -17.10 and a beta of 0.93. The company has a 50-day moving average price of $8.84 and a 200-day moving average price of $9.00.
Institutional Trading of GH Research
An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. increased its holdings in GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,686,689 shares of the company's stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company's stock.
GH Research Company Profile
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
See Also
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
